NCT05301530View on ClinicalTrials.gov

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

February 19, 2021

Conditions
Breast Cancer MetastaticBreast Cancer FemaleBreast Cancer Recurrent
Interventions
DRUG

Faceptor

NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.

DRUG

Herceptin

Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.

DRUG

Docetaxel

The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.

Trial Locations (2)

Unknown

19-8 Hospital, Hanoi

HCMC Oncology Hospital, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

Vietstar Biomedical Research

INDUSTRY

collaborator

MedProve Inc

UNKNOWN

lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY

NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | Biotech Hunter | Biotech Hunter